Oragenics Inc
$ 0.61
0.83%
02 Jun - close price
- Market Cap 2,729,700 USD
- Current Price $ 0.61
- High / Low $ 0.63 / 0.60
- Stock P/E N/A
- Book Value 1.41
- EPS -4.95
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.06 %
- ROE -3.11 %
- 52 Week High 5.24
- 52 Week Low 0.50
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-03-14 | 2024-11-13 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-14 | 2023-05-12 | 2023-03-29 |
| Reported EPS | -1.96 | -3.1 | -3.65 | -0.2664 | -0.3773 | -0.509 | -0.701 | -4.1378 | -0.8543 | -1.5066 | -0.15 | -1.1101 |
| Estimated EPS | 0 | 0 | None | None | None | None | None | None | None | -3 | -2.4 | -2.4 |
| Surprise | -1.96 | -3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4934 | 2.25 | 1.2899 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | 49.78% | 93.75% | 53.7458% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OGEN
2026-05-19 21:39:40
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company, announced it will present and host one-on-one meetings with investors at Sidoti's Micro-Cap Virtual Investor Conference on May 20-21, 2026. The presentation will occur on May 21st at 3:15 PM ET and will focus on the company's lead candidate, ONP-002, for concussion and mild traumatic brain injury. Investors can register for free to attend the presentation and schedule one-on-one meetings.
2026-05-19 13:10:01
Oragenics (OGEN) has progressed its ONP-002 Phase IIa trial in Australia, with active patient dosing and no serious adverse events reported. The company reported a cash balance of $6.1 million as of March 31, 2026, and an LOI for a CNS device. Oragenics plans to submit a full IND by the end of 2026 to enable U.S. trials.
2026-05-19 12:38:59
Oragenics, Inc., a clinical-stage biopharmaceutical company focused on neurological therapeutics, will present and host one-on-one meetings at Sidoti's Micro-Cap Virtual Investor Conference on May 20-21, 2026. The company will discuss its lead candidate, ONP-002, which is being developed as a treatment for concussion and mild traumatic brain injury, and its proprietary intranasal delivery technology. Investors can register for the presentation and one-on-one meetings via the Sidoti website.
2026-05-19 07:10:01
Oragenics, Inc. provided an investor update detailing progress on its ONP-002 Phase IIa clinical trial in Australia for concussion/mTBI, with patient enrollment and dosing underway at multiple sites. The company is also advancing regulatory steps for U.S. clinical trials, targeting FDA submissions by the end of 2026. Additionally, Oragenics has signed an LOI for a CNS-related medical device licensing agreement to expand its strategic pipeline.
2026-05-18 15:40:10
Oragenics Inc. is progressing with its Phase IIa clinical trial for ONP-002, an intranasal neurosteroid for concussion treatment, with active patient enrollment and dosing in Australia. The company also signed a Letter of Intent for a licensing agreement for a CNS-related medical device, specifically carving out rights for traumatic brain injury. Financially, Oragenics reported a cash balance of $6.1 million as of March 31, 2026, and its stock trades at $0.59 with a market cap of $2.55 million.
2026-05-18 12:40:10
Oragenics, Inc. (NYSE American: OGEN) has provided an investor update detailing progress on its Phase IIa clinical trial for ONP-002, a first-in-class intranasal neurosteroid for concussion/mTBI, which is now active in Australia with patient enrollment and dosing underway. The company is also advancing its U.S. IND program, targeting an FDA Type C Meeting Request in Q2 2026 and a full IND submission by the end of 2026. Additionally, Oragenics has signed a Letter of Intent for a licensing agreement for a complementary CNS-related medical device to expand its strategic pipeline.
